10x Genomics Trades Past Analyst Target, Atera Test Looms
An analyst upgraded 10x Genomics this week and declared the Atera turnaround "real," yet shares already trade at $65.12, above the $49.54 consensus price target, on a 320.3x forward multiple. With tra
TXG Stock Tops Analyst Target as Atera Faces Delivery Test
NEW YORK, August 23 —
10x Genomics, Inc. (TXG) sits in a peculiar position. An analyst declared its turnaround "real" this week, upgraded the stock, and immediately added that Atera "now has to deliver", a caveat that carries weight when shares already trade at $65.12, above the $49.54 analyst consensus price target, while trailing revenue has fallen 12.7%.
- TTM revenue $0.62 billion, down 12.7% year-over-year; trailing EPS -$0.59 despite four consecutive quarterly beats.
- Shares at $65.12 trade at 320.3x forward earnings, already above the $49.54 analyst consensus target.
- Gross margin 70.1%; $550 million cash against $80 million debt; TTM free cash flow $180 million.
Beats on a Shrinking Base
Four consecutive EPS beats, the most recent at 240% above consensus per the August 6 earnings disclosure, look impressive until set against revenue still contracting on a trailing twelve-month basis. 10x Genomics sells three instrument platforms: Chromium for single-cell analysis, Visium for spatial genomics, and Xenium for in-situ RNA detection, plus consumables and software to academic labs, biopharma firms, and government institutions across four global regions. The beats reflect tighter cost control on a declining revenue stream, not accelerating instrument placements. Trailing EPS remains -$0.59; each quarterly beat shows cost discipline, not a profitability turn.
The Balance Sheet Buys Time
The financial structure gives 10x room to wait. The company carries $550 million in cash against $80 million in total debt; gross margin runs at 70.1%, and trailing twelve-month free cash flow reached $180 million, the installed base generates cash even as the top line shrinks. Chromium recently added protein detection capability, extending its reach beyond RNA and methylation profiling; that TAM expansion could drive higher consumables pull-through per instrument. Investors modeling the recovery can stress-test the assumptions with the DCF calculator. The upgrading analyst declined to say whether that expansion broadens Atera's commercial case.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| TXG | $8.5B | 320.3x | +362.8% |
| TWST | $9.1B | n/a | +431.5% |
| BEAM | $3.1B | n/a | +81.0% |
| PACB | $420M | n/a | +2.3% |
| VCYT | $3.4B | 21.7x | +43.2% |
| GH | $22.9B | n/a | +175.8% |
Revenue Is the Test
Already trading past the analyst consensus target, TXG's price embeds an Atera adoption cycle that hasn't appeared in the revenue line. Short interest at 17.6% of the float signals a significant cohort doubts the timeline; institutional ownership at 112% of shares outstanding reflects aggressive accumulation on the other side. The variable that settles it is sequential revenue growth in the next earnings report: a return to top-line expansion validates what a 320.3x forward multiple demands; continued contraction raises the question of whether the current price or the consensus target is more anchored to the fundamentals. Run the free TXG deep-dive →
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Is 10x Genomics stock above the analyst price target?
Yes. Shares trade at $65.12, above the $49.54 analyst consensus price target, after an analyst upgrade this week declared the company's turnaround "real." The premium implies an Atera adoption cycle that has not yet appeared in the trailing revenue line, which fell 12.7% year over year. The stock carries a 320.3x forward earnings multiple, making sequential revenue growth the key variable for whether the price holds.
What is 10x Genomics Atera?
The article describes an "Atera adoption cycle" that TXG's current stock price is already pricing in, and the upgrading analyst stated that Atera "now has to deliver." Whether that commercial case broadens is the question the analyst declined to answer directly. Sequential revenue growth in the next earnings report is described as the clearest signal of whether the adoption cycle is underway.
Why does 10x Genomics trade at 320x forward earnings?
Shares carry a 320.3x forward earnings multiple because investors are pricing in a top-line recovery that trailing results have not yet confirmed. Four consecutive EPS beats, including a 240% beat above consensus on the August 6 disclosure, have supported the premium. Trailing EPS remains negative at -$0.59 and trailing revenue declined 12.7%, so the multiple requires visible revenue growth to be sustained.
What is the short interest in 10x Genomics?
Short interest stands at 17.6% of the float, reflecting investor skepticism about the timeline for an Atera adoption cycle. On the other side, institutional ownership at 112% of shares outstanding signals aggressive accumulation. The next sequential revenue print is described as the variable that settles the disagreement between these two cohorts.
What are 10x Genomics three instrument platforms?
10x Genomics sells Chromium for single-cell analysis, Visium for spatial genomics, and Xenium for in-situ RNA detection, alongside consumables and software sold to academic labs, biopharma firms, and government institutions across four global regions. Chromium recently added protein detection capability, extending its analytical scope beyond RNA and methylation profiling. The article notes this TAM expansion could support higher consumables pull-through per instrument.
An analyst upgraded 10x Genomics within the past two days, declaring the turnaround 'real' — but specifically adding that 'Atera now has to deliver.' Shares have climbed to $65.12, already above the analyst consensus target of $49.54, while trailing revenue has fallen 12.7% and the stock trades at 320 times forward earnings.